A clinical study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) patients with relapsed or refractory advanced esophagogastric adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs DKN 01 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 16 Apr 2018 Preliminary results presented in a Leap Therapeutics Media Release.
- 16 Apr 2018 According to a Leap Therapeutics media release, preliminary results from the dose escalation phase of this study presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting.
- 23 Feb 2018 According to a Leap Therapeutics media release, interim data are expected in 2018.